Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $2.77 in the prior trading day, Health Catalyst Inc (NASDAQ: HCAT) closed at $2.92, up 5.42%. In other words, the price has increased by $5.42 from its previous closing price. On the day, 1.0 million shares were traded. HCAT stock price reached its highest trading level at $2.945 during the session, while it also had its lowest trading level at $2.71.
Ratios:
Our goal is to gain a better understanding of HCAT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.86 and its Current Ratio is at 1.86. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.50.
Cantor Fitzgerald Downgraded its Overweight to Neutral on August 08, 2025, while the target price for the stock was maintained at $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 05 ’25 when Landry Benjamin sold 6,175 shares for $3.35 per share. The transaction valued at 20,705 led to the insider holds 141,812 shares of the business.
BENJAMIN LANDRY bought 6,175 shares of HCAT for $20,378 on Sep 05 ’25. On Sep 02 ’25, another insider, Linda Llewelyn, who serves as the Officer of the company, bought 2,854 shares for $3.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 206534176 and an Enterprise Value of 287113184. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.65 while its Price-to-Book (P/B) ratio in mrq is 0.62. Its current Enterprise Value per Revenue stands at 0.908 whereas that against EBITDA is -17.042.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.74, which has changed by -0.66930914 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $9.24, while it has fallen to a 52-week low of $2.02. The 50-Day Moving Average of the stock is 2.38%, while the 200-Day Moving Average is calculated to be -20.44%.
Shares Statistics:
The stock has traded on average 674.62K shares per day over the past 3-months and 913270 shares per day over the last 10 days, according to various share statistics. A total of 70.62M shares are outstanding, with a floating share count of 65.96M. Insiders hold about 6.75% of the company’s shares, while institutions hold 78.28% stake in the company. Shares short for HCAT as of 1763078400 were 6060201 with a Short Ratio of 8.98, compared to 1760486400 on 6632700. Therefore, it implies a Short% of Shares Outstanding of 6060201 and a Short% of Float of 9.7600006.
Earnings Estimates
The performance of Health Catalyst Inc (HCAT) in the stock market is under the watchful eye of 8.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.08, with high estimates of $0.15 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.25 and $0.18 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.35, with 10.0 analysts recommending between $0.62 and $0.21.
Revenue Estimates
11 analysts predict $73.94M in revenue for. The current quarter. It ranges from a high estimate of $75.04M to a low estimate of $73.5M. As of. The current estimate, Health Catalyst Inc’s year-ago sales were $79.61MFor the next quarter, 11 analysts are estimating revenue of $74.21M. There is a high estimate of $76.4M for the next quarter, whereas the lowest estimate is $71.96M.
A total of 12 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $311.49M, while the lowest revenue estimate was $309.9M, resulting in an average revenue estimate of $310.26M. In the same quarter a year ago, actual revenue was $306.58MBased on 12 analysts’ estimates, the company’s revenue will be $302.08M in the next fiscal year. The high estimate is $307.5M and the low estimate is $298.1M.
